Pharmacology of the calcium sensing receptor

Clinical Cases in Mineral and Bone Metabolism

Volumn 10, Issue 3, 2013, Pages 162-165

  Filopanti, Marcello ^a   Corbetta, Sabrina ^b,c   Barbieri, Anna Maria ^b   Spada, Anna ^a,b  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c IRCCS POLICLINICO SAN DONATO   (Italy)

Author keywords

Calcium metabolism; Calcium sensing receptor; CASR; Cinacalcet; Ronacaleret.

Indexed keywords

EID: 84894160782     PISSN: 17248914     EISSN: 19713266     Source Type: Journal    
DOI: None     Document Type: Review

References (43)

1. Brown EM. Chnical lessons from the calcium sensing receptor. Nat Chn Pract Endocriniol Metab 2007 3:122-33. (Pubitemid 46146965)
2. Brown EM, MacLeod RJ. Extracellular calcium sensing and extracellular calcium signaling. Physiol Rev 200181 239-297. Review. (Pubitemid 32096177)
3. OdaY,TuCLIaiS,etaThecalciimsensiigreceptoranditsalterrwtively spliced form in kerahnocyte differentiation. J Bid (Them 1998 273(36) 23344-52.
4. GarrettJE, Capuano IV, Haromerland LG, etal. Molecular doning and functional expression of human parathyroki calcium receptor cONAs. J Bid (Them 1995270(21):12919-25.
5. Hu J, Spiegel AM. Structire and function of the human calcium-sensing receptor: Insights from natural and engineered mutations and ailostenc modulators. J Cell Mol Med 2007:1 1 (5) :908-22. Review. (Pubitemid 350037042)
6. Huang Y, Thou Y, Yang W, et al. Identification and dissection of Ca(2+)-binding sites in the extracellular domain of Ca(2+)-sensing receptor. J 8101 Chem 2007:282(26):1 9000-10. (Pubitemid 47100150)
7. Ray K, Northup J. Evidence for distinct cation and calcimimetic compound (NPS 568) recognition domains in the transmembrane regions of the human Ca2+ receptor. J Biol Ctrem 2002:277(21):18908-13. (Pubitemid 34952451)
8. Hammerland LG, Krapcho KJ, Garrett JE, et at. Domains determining hgand specificity for Ca2+ receptors. Mol Pharmacol 1999:55:642-648. (Pubitemid 29165428)
9. Huang C, Miller RT. Novel Ca receptor signaling pathways for control of renal ion transport. Curr Opin Nephrol Hypertens 2010:1 9(1 ):106-12. Review. in.
10. Brauner-Osborne H, Jensen AA. et at. The agonist-binding domain of the calcium-sensing receptor is located at the amino-terminal domain.J Bid Chem2 1999:74:18382-18386.
11. Quinn SJ, Ye CP, Diaz R, et at. The Ca2+-sensing receptor: A target for potyamines. Am J Physiol Cell Ptiysiol 1997273:C1315-C1323.
12. Feng J, Petersen CD, Coy OH, et at. Calcium-sensing receptor is a physiologic muhirnodal chemosensor regulating gastric G-cell growth and gastrin secretion. Proc Nail Acad Sd USA. 2010:107(41):17791.6.
13. Corrigrave AD, Mun HC, Lok HC. Aromatic L-amino acids activate the calcium-sensing receptor. J Nutr 2007:137(6 Suppi 1):1524S-1527S.
14. Broadhead GK, Mun HC, Avlani VA, et at. Allosteric modulation of the calcium-sensing receptor by gamnia-glutamyl peptides: Inhibition of PTH secretion, suppression of intracellular cAMP levels, and a common rnechanism of action with L-anino acids. J Biol Chem 2011286(11 ):8786-97.
15. Theman TA, Collins MT. The role of the calcium-sensing receptor in bone biology and paihophysiology. Cur Pharm Biotecfrrol 2009:10(3)289-301 Review.
16. Nemeth EF. Steffey ME, Hammerland LG, of al. Caidmimetics with potent and selective activity on the parathyroid calcium receptor. Proc Nail Acad Sci USA 19985(7):4O4O-5. (Pubitemid 28173250)
17. Haimuertand LG, GarrettJE, Hung BC, et at. Allosteric activation of the Ca2+ receptor expressed in xenopus laevis occytes by NPS 467 or NPS 568. Mdi Pharmacol 1 998:53:1083-1 088. (Pubitemid 28280452)
18. Cavanaugh A, Huang Y, Breitwieser GE. Behind the curtain: Cellular mechanisms for allosteric modulation of calcium-sensing receptors. Br J Pharmacol 2012:165(6):1670-7. Review.
19. Nemeth EF and Fox J. Calcin-ulmetic compounds: A direct approach to contrd-ng plasma levels of parathyroid hermone in hyperparathyroidism.Trends Endocrinol Metab 1999:l0:66-71. (Pubitemid 29287825)
20. Nemeth EF, Heaton WH, Miller M, et al. Pharmacodynamics of the type II calcinimetic compound cinacalcet HQ. J Pharmacol Exp Ther2004308.627-635. (Pubitemid 38134225)
21. Hu J, Reyes-Cruz G, et al. AM. Identification of acidic residues in the extracellular loops of the seven-transmembrane domain of the human Ca2+ receptor critical for response to Ca2+ and a positive allosteric modulator. J Biol Chem 2002277(48):46622-31. (Pubitemid 35417662)
22. Petrel C Kessler A, Dauban P, et al. Positive and negative allosteric mod-ulators of the Ca2+-sensmg receptor interact within overiapping but not identical binding sites in the transmembrane domain. J Biol Chem 2004279(18):1 8990-7. (Pubitemid 38623329)
23. Komaba H, Kakuta T, Fukagawa M. Diseases of the parathyroid gland in chronic kidney disease. Clin Exp Nephrol 2011 :15(6):797-809.
24. Drüeke TB, Ritz E. Treatment of secondary hyperparathyroidism in CKD patients with cinacalcet and/or vitann D derivatives. Clin JAm Soc Neplirol 2009:4(1):234-41.
25. Sverberg SJ, Rutin MR, Faiman C, et al. Cinacaicet hydrochloride reduces the serum calcium concentration in inoperable parathyroid carcinoma. J Clin Endocrinol Metab 2007:92(10):3803-8. (Pubitemid 47607626)
26. Peacock M, Bolognese MA, Borof sky M, at al. Cinacalcet treatment of pamaiy hyperparathyroidism: Biochemical and bone densitometric outcomes in a five-year study. J Gun Endocrinol Metab 2009:94(12)4860-7.
27. Peacock M, Bezikian JP, Bolognese MA, at al. Cinacalcet HCl reduces hypercalcemia in pnrnanj hyperparathyroidism across a wide spectrum ot disease severity. J Gun Endocrinol Metab 2011 :96(1):E9-18.
28. Falchetti A. Cilotti A, Vaggelli L, et al. A patient with MEN 1-associated hyperparathyroideni, responsive to cuiacalcet Nat Clin Pract Endoainol Metab 2008:4:351-7.
29. Mayes VJ, Monson JP, Chew SL, eta). Clinical use of cinacalcet in MEN1 hperparathyroidism. lntJ Endocrinol 2010. doi:10.l 155/2010)906163.
30. Filopanti M, Verga U, Errnetici F, at al. MEN1-related hyperparathyroidism: Response to cinacaicet and its relationship with the calcium-sensing receptor gene variant Arg99OGly. EurJ Endocrinol 201 2:167(2):157-64.
31. Vamauchi M, Sugimoto T, Yamaguchi T, eta]. Association of polymorphic alleles of the calcium-sensing receptor gene with the dinical severity of primary hyperparathyroidism. Gun Endocrinol 2001 :55:373-379. (Pubitemid 32825492)
32. Corbetta S, Eller-Vainicher C, Filopanti M, eta). R990G polymorphism of the calcium-sensing receptor and rena] calcium excretion in patients with primary hyperparathyroidism. Fur J Endocnnol 2006:1 55:687-92. (Pubitemid 44857492)
33. Rothe HM. Shapiro WB, Sun WY, at aL Calcium-sensing receptorene poly morphism R990G and its possible effect on response to Cinacalcet HCt. Pharmacogenetics and Genomics 2005:1529-34.
34. Terranegra A, Ferraretto A, Dogliotti E, eta). Calcimimetic R-568 effects on activity of R990G polymorphism of calcium-sensing receptor. J McI Endoamnol 201 0:45(4):245-56.
35. Timmers HJ, Karperien M, Hamdy NA. eta). Normalization of serum cal cium by cinacalcet in a patient with hyperca)caemia due to a De novo in activating mutation of the calcium-sensing receptor. J Intern Med 2006:260(2):1 77-82. (Pubitemid 44051343)
36. Brown EM. Clinical utility of calcimimetics targeting the extracellular calci um-sensing receptor (CaSR). Biochem Pharmacol 2010:80(3)297-307. Re view.
37. Han SL Wan SL. Effect of tenparatide on bone mineral density and frac ture in postmenopausal osteoporosis: Meta-analysis of randomised con trolled trials. mt J Gun Pract 2012:66(2):199-209. Review.
38. Nemeth EF. The search for calcium receptor antagonists (calcilytics).J Mol Endocrinol 200229:15-21. (Pubitemid 34965743)
39. Nemeth EF, Delmar EG, Heaton WL, et al. Calcilytic compounds: Potent and selective Ca2+ receptor antagonists that stimulate secretion of parathyroid hormone. J Pharmacd Exp Ther 2001299.323-331. (Pubitemid 32905150)
40. Kumar S. Matheny Cl, Hoffman SJ. at at. An orally active calcium-sens ing receptor antagonist that transiently increases plasma concentrations of PTh and stimulates bone formation. Bone 2010:46:534-542.
41. Amy BJ, Seethala R, MaZ, at a). A novel calcium-sensing receptor antagonist transiently stimulates parathyroid hormone secretion in vivo.Endociinoto gy 2005:146:2015-2022. (Pubitemid 40396912)
42. Fitzpatrick LA, Dabrowski CE, Cicconetti G, eta]. Ronacaleret, a calcium-sensing receptor antagorsst, increases trabecular but not cortical bone in postmenopausal women. J Bone Miner Res 201227(2):255-62.
43. Kumar S, Matheny CJ, Hoffman SJ, et al. An orally active calcium-sens ing receptor antagonist that transiently increases plasma concentrations of PTh and stimulates bone formation. Bone 2010:46:534-542.